These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8054911)

  • 41. A pilot study of busulfan and melphalan as preparatory regimen prior to allogeneic bone marrow transplantation in refractory or relapsed hematological malignancies.
    Vey N; De Prijck B; Faucher C; Stoppa AM; Sainty D; Lafage M; Bouabdallah R; Chabannon C; Camerlo J; Gastaut JA; Maraninchi D; Blaise D
    Bone Marrow Transplant; 1996 Sep; 18(3):495-9. PubMed ID: 8879608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
    Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
    Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation.
    Rigden JP; Cornetta K; Srour EF; Hanna M; Broun ER; Hromas R; Baute J; Hilton J; Cox E; Rubin L; Gonin R; Tricot G
    Bone Marrow Transplant; 1996 Nov; 18(5):913-9. PubMed ID: 8932845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Allogeneic bone marrow transplantation for children with acute lymphoblastic leukemia conditioned with busulfan, cyclophosphamide and melphalan.
    Carpenter PA; Marshall GM; Giri N; Vowels MR; Russell SJ
    Bone Marrow Transplant; 1996 Sep; 18(3):489-94. PubMed ID: 8879607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides.
    Molina A; Zain J; Arber DA; Angelopolou M; O'Donnell M; Murata-Collins J; Forman SJ; Nademanee A
    J Clin Oncol; 2005 Sep; 23(25):6163-71. PubMed ID: 16135483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Jerjis S; Roovers E; Muus P; Schaap N; de Witte T
    Bone Marrow Transplant; 1998 Jul; 22(1):13-9. PubMed ID: 9678790
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Unrelated donor bone marrow transplantation for Fanconi anemia.
    Davies SM; Khan S; Wagner JE; Arthur DC; Auerbach AD; Ramsay NK; Weisdorf DJ
    Bone Marrow Transplant; 1996 Jan; 17(1):43-7. PubMed ID: 8673053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic bone marrow transplantation for childhood leukemia following a busulfan and melphalan preparative regimen.
    Matsuyama T; Kojima S; Kato K
    Bone Marrow Transplant; 1998 Jul; 22(1):21-6. PubMed ID: 9678791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bone marrow transplantation from unrelated donors for patients with adult T-cell leukaemia/lymphoma.
    Nakase K; Hara M; Kozuka T; Tanimoto K; Nawa Y
    Bone Marrow Transplant; 2006 Jan; 37(1):41-4. PubMed ID: 16247419
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children.
    Hobbs JR; Hugh-Jones K; Shaw PJ; Downie CJ; Williamson S
    Bone Marrow Transplant; 1986 Dec; 1(2):201-8. PubMed ID: 2971409
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression of messenger RNA for GM-CSF by blood mononuclear cells after allogeneic bone marrow transplantation.
    Atkinson K; Altavilla V; Cooley M
    Behring Inst Mitt; 1988 Aug; (83):330-4. PubMed ID: 3071349
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Busulfan and cyclophosphamide as conditioning regimen for autologous BMT in acute lymphoblastic leukemia.
    Porcellini A; Manna A; Moretti L; Carotenuto M; Greco MM; Bodenizza C
    Bone Marrow Transplant; 1989 May; 4(3):331-3. PubMed ID: 2659120
    [No Abstract]   [Full Text] [Related]  

  • 58. Bone marrow transplantation from unrelated donors for genetic diseases following conditioning with Busulphan and Cyclophosphamide.
    Vellodi A; Jurges E; el-Tumi M; Abdul-Ahad A; Hobbs JR
    Bone Marrow Transplant; 1991; 7 Suppl 2():70. PubMed ID: 1878726
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2.
    Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos B; Tutschka P; Kapoor N
    Blood; 1992 Sep; 80(5):1352-7. PubMed ID: 1515648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High-dose busulphan and cyclophosphamide as the primary preparative regimen for marrow transplantation in chronic myeloid leukaemia.
    Urban EC; Kroisel P
    Bone Marrow Transplant; 1987 Aug; 2(2):217-8. PubMed ID: 3332170
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.